Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effectiveness of BNT162b2 Vaccine in Adolescents during Outbreak of SARS-CoV-2 Delta Variant Infection, Israel, 2021
Aharona Glatman‐Freedman, Yael Hershkovitz, Zalman Kaufman, et al.
Emerging infectious diseases (2021) Vol. 27, Iss. 11, pp. 2919-2922
Open Access | Times Cited: 70

Showing 1-25 of 70 citing articles:

Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review
Thibault Fiolet, Yousra Kherabi, Conor-James MacDonald, et al.
Clinical Microbiology and Infection (2021) Vol. 28, Iss. 2, pp. 202-221
Open Access | Times Cited: 820
Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age
Emmanuel B. Walter, Kawsar R. Talaat, Charu Sabharwal, et al.
New England Journal of Medicine (2021) Vol. 386, Iss. 1, pp. 35-46
Open Access | Times Cited: 543
Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis
Baoqi Zeng, Le Gao, Qingxin Zhou, et al.
BMC Medicine (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 234
BNT162b2 Protection against the Omicron Variant in Children and Adolescents
Ashley M. Price, Samantha M. Olson, Margaret M. Newhams, et al.
New England Journal of Medicine (2022) Vol. 386, Iss. 20, pp. 1899-1909
Open Access | Times Cited: 221
COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection
Wei-Yu Chi, Yen-Der Li, Hsin‐Che Huang, et al.
Journal of Biomedical Science (2022) Vol. 29, Iss. 1
Open Access | Times Cited: 166
Effectiveness of BNT162b2 Vaccine against Critical Covid-19 in Adolescents
Samantha M. Olson, Margaret M. Newhams, Natasha Halasa, et al.
New England Journal of Medicine (2022) Vol. 386, Iss. 8, pp. 713-723
Open Access | Times Cited: 104
Association of COVID-19 Vaccination With Symptomatic SARS-CoV-2 Infection by Time Since Vaccination and Delta Variant Predominance
Amadea Britton, Katherine E. Fleming-Dutra, Nong Shang, et al.
JAMA (2022) Vol. 327, Iss. 11, pp. 1032-1032
Open Access | Times Cited: 81
Effectiveness of Pfizer-BioNTech mRNA Vaccination Against COVID-19 Hospitalization Among Persons Aged 12–18 Years — United States, June–September 2021
Samantha M. Olson, Margaret M. Newhams, Natasha Halasa, et al.
MMWR Morbidity and Mortality Weekly Report (2021) Vol. 70, Iss. 42, pp. 1483-1488
Open Access | Times Cited: 99
Effectiveness of BNT162b2 against COVID-19 in adolescents
Annabel Powell, Freja Kirsebom, Julia Stowe, et al.
The Lancet Infectious Diseases (2022) Vol. 22, Iss. 5, pp. 581-583
Open Access | Times Cited: 60
Immunogenicity, effectiveness, and safety of COVID-19 vaccines among children and adolescents aged 2–18 years: an updated systematic review and meta-analysis
Peng Gao, Liangyu Kang, Jue Liu, et al.
World Journal of Pediatrics (2023) Vol. 19, Iss. 11, pp. 1041-1054
Open Access | Times Cited: 21
Safety and effectiveness of BNT162b2 mRNA Covid-19 vaccine in adolescents
Young June Choe, Seonju Yi, Insob Hwang, et al.
Vaccine (2021) Vol. 40, Iss. 5, pp. 691-694
Open Access | Times Cited: 44
Effectiveness of BBIBP-CorV, BNT162b2 and mRNA-1273 vaccines against hospitalisations among children and adolescents during the Omicron outbreak in Argentina: A retrospective cohort study
Soledad González, Santiago Olszevicki, Alejandra Gaiano, et al.
The Lancet Regional Health - Americas (2022) Vol. 13, pp. 100316-100316
Open Access | Times Cited: 33
The effectiveness of coronavirus disease 2019 (COVID-19) vaccine in the prevention of post–COVID-19 conditions: A systematic literature review and meta-analysis
Alexandre R. Marra, Takaaki Kobayashi, Hiroyuki Suzuki, et al.
Antimicrobial Stewardship & Healthcare Epidemiology (2022) Vol. 2, Iss. 1
Open Access | Times Cited: 33
Immunologic response, Efficacy, and Safety of Vaccines against COVID-19 Infection in Healthy and immunosuppressed Children and Adolescents Aged 2 – 21 years old: A Systematic Review and Meta-analysis
Sara Sadeghi, Yasamin Kalantari, Sima Shokri, et al.
Journal of Clinical Virology (2022) Vol. 153, pp. 105196-105196
Open Access | Times Cited: 32
Recent advances in nanotechnology-based COVID-19 vaccines and therapeutic antibodies
Lanying Du, Yang Yang, Xiujuan Zhang, et al.
Nanoscale (2022) Vol. 14, Iss. 4, pp. 1054-1074
Open Access | Times Cited: 31
Effectiveness of mRNA-1273, BNT162b2, and BBIBP-CorV vaccines against infection and mortality in children in Argentina, during predominance of delta and omicron covid-19 variants: test negative, case-control study
Juan Manuel Castelli, Analía Rearte, Santiago Olszevicki, et al.
BMJ (2022), pp. e073070-e073070
Open Access | Times Cited: 29
Safety and efficacy of the COVID-19 vaccine in children and/or adolescents:A meta-analysis
Wencheng Xu, Jiake Tang, Chen Chen, et al.
Journal of Infection (2022) Vol. 84, Iss. 5, pp. 722-746
Open Access | Times Cited: 28
Vaccine-induced protection against SARS-CoV-2 requires IFN-γ-driven cellular immune response
Xiaolei Wang, Terrence Tsz‐Tai Yuen, Ying Dou, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 20
BNT162b2 Effectiveness Against Delta and Omicron Variants of Severe Acute Respiratory Syndrome Coronavirus 2 in Adolescents Aged 12–17 Years, by Dosing Interval and Duration
Iulia G Ionescu, Danuta M. Skowronski, Chantal Sauvageau, et al.
The Journal of Infectious Diseases (2023) Vol. 227, Iss. 9, pp. 1073-1083
Open Access | Times Cited: 16
Effectiveness of BNT162b2 vaccine against SARS-CoV-2 Delta and Omicron infection in adolescents, Norway, August 2021 to January 2022
Lamprini Veneti, Jacob Dag Berild, Sara Viksmoen Watle, et al.
International Journal of Infectious Diseases (2023) Vol. 130, pp. 182-188
Open Access | Times Cited: 16
Effectiveness of Heterologous Coronavirus Disease 2019 (COVID-19) Vaccine Booster Dosing in Brazilian Healthcare Workers, 2021
Alexandre R. Marra, João Luiz Miraglia, Daniel Tavares Malheiros, et al.
Clinical Infectious Diseases (2022) Vol. 76, Iss. 3, pp. e360-e366
Open Access | Times Cited: 24
Effectiveness of BNT162b2 Vaccine Booster against SARS-CoV-2 Infection and Breakthrough Complications, Israel
Aharona Glatman‐Freedman, Michal Bromberg, Yael Hershkovitz, et al.
Emerging infectious diseases (2022) Vol. 28, Iss. 5, pp. 948-956
Open Access | Times Cited: 21
Vaccine effectiveness with BNT162b2 (Comirnaty, Pfizer-BioNTech) vaccine against reported SARS-CoV-2 Delta and Omicron infection among adolescents, Norway, August 2021 to January 2022
Lamprini Veneti, Jacob Dag Berild, Sara Viksmoen Watle, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 20
Effectiveness of the BNT162b2 (Pfizer-BioNTech) Vaccine in Children and Adolescents: A Systematic Review and Meta-Analysis
Jewel Maria Sabu, Izza Zahid, Namitha Jacob, et al.
Vaccines (2022) Vol. 10, Iss. 11, pp. 1880-1880
Open Access | Times Cited: 20
Post-vaccination infection rates and modification of COVID-19 symptoms in vaccinated UK school-aged children and adolescents: A prospective longitudinal cohort study
Erika Molteni, Liane S. Canas, Kerstin Kläser, et al.
The Lancet Regional Health - Europe (2022) Vol. 19, pp. 100429-100429
Open Access | Times Cited: 19
Page 1 - Next Page

Scroll to top